OICR Innovation to Implementation

To accelerate translational cancer research so that precise, impactful and cost-effective treatments can benefit cancer patients, OICR has implemented a new Clinical Translation Pathway (CTP) to support preclinical, clinical, and convergent research. The CTP consists of four separate funding streams and is currently inviting applications for the Innovation to Implementation (I2I) funding opportunity which is focused on overcoming barriers to the mobilization, or uptake, of knowledge required to facilitate adoption of research into policy or healthcare. OICR is committed to providing research funding to help support a sustainable health system that enables fair and equitable access to cancer interventions. 

Cancer Therapeutics Innovation Pipeline – Request for applications

The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.